Last updated: 11/07/2018 18:35:26
Characterization of Changes in Regional Brain Activity Associated With Sigmoid Sensitization in IBS Patients Using Positron Emission Tomography (PET) With and Without Alosetron Therapy
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Characterization of Changes in Regional Brain Activity Associated With Sigmoid Sensitization in IBS Patients Using Positron Emission Tomography (PET) With and Without Alosetron Therapy
Trial description: Characterization of Changes in Regional Brain Activity Associated With Sigmoid Sensitization in IBS Patients Using Positron Emission Tomography (PET) With and Without Alosetron Therapy
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Abstract: Differences between drug and placebo-mediated improvement in irritable bowel syndrome. Berman, Steve M., Jarcho, Johanna, Suyenobu, Brandall, Naliboff, Bruce, Lin Chang, and Mayer, Emeran A. 61st Annual Scientific Meeting of the American Psychosomatic Society 3/5/2003 Phoenix, AZ; USA
Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron, Berman SM, Chang L, Suyenobu B, Derbyshire SW, Stains J, Fitzgerald L, Mandelkern M, Hamm L, Vogt B, Naliboff BD, Mayer EA. Gastroenterology 123(4):969-977, 2002
The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients, Mayer EA. Berman S. Derbyshire SWG. Suyenobu B. Chang L. Fitzgerald L. Mandelkern M. Hamm L. Vogt B. Naliboff BD, Alimentary Pharmacology & Therapeutics. 16(7):1357-1366, 2002
Medical condition
Irritable Colon
Product
alosetron
Collaborators
Not applicable
Study date(s)
May 1997 to May 1999
Type
Not applicable
Phase
2
Participation criteria
Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1999-20-05
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website